These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. Sang CN J Pain Symptom Manage; 2000 Jan; 19(1 Suppl):S21-5. PubMed ID: 10687335 [TBL] [Abstract][Full Text] [Related]
7. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Wiesenfeld-Hallin Z Drugs; 1998 Jan; 55(1):1-4. PubMed ID: 9463786 [TBL] [Abstract][Full Text] [Related]
8. Small molecules targeting the NMDA receptor complex as drugs for neuropathic pain. Planells-Cases R; Pérez-Payá E; Messeguer A; Carreño C; Ferrer-Montiel A Mini Rev Med Chem; 2003 Nov; 3(7):749-56. PubMed ID: 14529515 [TBL] [Abstract][Full Text] [Related]
9. The use of NMDA-receptor antagonists in the treatment of chronic pain. Hewitt DJ Clin J Pain; 2000 Jun; 16(2 Suppl):S73-9. PubMed ID: 10870744 [TBL] [Abstract][Full Text] [Related]
10. The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Christoph T; Schiene K; Englberger W; Parsons CG; Chizh BA Neuropharmacology; 2006 Jul; 51(1):12-7. PubMed ID: 16616769 [TBL] [Abstract][Full Text] [Related]
12. The NMDA receptor complex: a long and winding road to therapeutics. Wood PL IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895 [TBL] [Abstract][Full Text] [Related]
13. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Boyce S; Wyatt A; Webb JK; O'Donnell R; Mason G; Rigby M; Sirinathsinghji D; Hill RG; Rupniak NM Neuropharmacology; 1999 May; 38(5):611-23. PubMed ID: 10340299 [TBL] [Abstract][Full Text] [Related]
14. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Abe T; Matsumura S; Katano T; Mabuchi T; Takagi K; Xu L; Yamamoto A; Hattori K; Yagi T; Watanabe M; Nakazawa T; Yamamoto T; Mishina M; Nakai Y; Ito S Eur J Neurosci; 2005 Sep; 22(6):1445-54. PubMed ID: 16190898 [TBL] [Abstract][Full Text] [Related]
15. NMDA receptors as targets for drug action in neuropathic pain. Parsons CG Eur J Pharmacol; 2001 Oct; 429(1-3):71-8. PubMed ID: 11698028 [TBL] [Abstract][Full Text] [Related]
16. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. Chizh BA J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654 [TBL] [Abstract][Full Text] [Related]
17. Methadone for neuropathic pain: a new use for an old drug? Watson CP Can J Neurol Sci; 2005 Aug; 32(3):271-2. PubMed ID: 16225164 [No Abstract] [Full Text] [Related]
18. NMDA receptor antagonists and glycine site NMDA antagonists. Madden K Curr Med Res Opin; 2002; 18 Suppl 2():s27-31. PubMed ID: 12365826 [TBL] [Abstract][Full Text] [Related]
19. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Medvedev IO; Malyshkin AA; Belozertseva IV; Sukhotina IA; Sevostianova NY; Aliev K; Zvartau EE; Parsons CG; Danysz W; Bespalov AY Neuropharmacology; 2004 Aug; 47(2):175-83. PubMed ID: 15223296 [TBL] [Abstract][Full Text] [Related]
20. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Lipton SA NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]